Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

AstraZeneca to buy US-listed Fusion Pharma for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn. Fusion specialises in radioconjugates, which combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.

AstraZeneca will pay $21 a share for Fusion, a premium of more than 97% to the US-listed company's closing price on Monday and a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4bn.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

Hummingbird announces restart at Kouroussa
(Sharecast News) - Hummingbird Resources announced the remobilization of Corica Mining Services at the Kouroussa Gold Mine in Guinea on Friday, after a work stoppage on March 17.
Drilling to start on Oracle's Northern Zone project
(Sharecast News) - Oracle Power announced on Friday that drilling is set to start next week at the Northern Zone Gold Project, 25 kilometres east of Kalgoorlie in Western Australia.
Fulcrum Metals extends date for sale of uranium assets
(Sharecast News) - Fulcrum Metals announced an extension to the completion date for the proposed sale of its Saskatchewan uranium projects to Terra Balcanica Resources on Friday.
PipeHawk subsidiary awarded £0.75m contract
(Sharecast News) - PipeHawk announced on Friday that an unnamed building materials company had awarded its subsidiary QM Systems a significant contract.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.